Damian Marron

Damian Marron currently works at Circio Holding ASA, as Chairman from 2020, Cytoseek Ltd., as Non-Executive Chairman, Imophoron Ltd., as Non-Executive Chairman, Indegra Therapeutics Ltd., as Chairman, Onya Therapeutics Ltd., as Chairman, Nicox SA, as Chairman from 2024, Cantargia AB, as Director from 2025, Loxbridge Research LLP, as Director, Agalimmune Ltd., as Director, Resolys Bio, Inc., as Director from 2018, and Treehill Partners, LLC, as Head-Biopharma.
Dr. Marron also formerly worked at Cytheris SA, as Chief Executive Officer, Trophos SA, as Chief Executive Officer, Sangamo Therapeutics France SAS, as Chief Executive Officer & Director from 2013 to 2015, PepGen Ltd., as Chairman, France Biotech Association, as Director, Bone Therapeutics SA, as Independent Non-Executive Director, Theralpha, as Director, Nicox SA, as Executive Vice President-Corporate Development from 2002 to 2008, Orphan Europe SARL, as Manager-Drug Group, Bausch & Lomb (Australia) Pty Ltd., as Head-European Development Business in 2013, Rhone-Poulenc Rorer BV, as Principal from 1991 to 2013, and Glaxo Wellcome Immobilière de Recherche SA, as Principal from 1986 to 2013.
Dr. Marron received his undergraduate degree in 1985 from The University of Liverpool.